Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Balancing Between Ischemic and Bleeding Risk in PCI Patients With 'Bi-Risk'

  • Mahn-Won Park (Division of Cardiology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2022.01.12
  • Accepted : 2022.02.03
  • Published : 2022.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Kim HK, Ahn Y, Chang K, et al. 2020 Korean Society of Myocardial Infarction expert consensus document on pharmacotherapy for acute myocardial infarction. Korean Circ J 2020;50:845-66. https://doi.org/10.4070/kcj.2020.0196
  2. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009;30:1457-66. https://doi.org/10.1093/eurheartj/ehp110
  3. Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017;38:804-10.
  4. Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet 2019;393:2503-10. https://doi.org/10.1016/S0140-6736(19)30474-X
  5. Cao D, Mehran R, Dangas G, et al. Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients. J Am Coll Cardiol 2020;75:2711-22. https://doi.org/10.1016/j.jacc.2020.03.070
  6. Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med 2021;385:1643-55. https://doi.org/10.1056/NEJMoa2108749
  7. TCT. MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk 2021 [Internet]. New York (NY): TCT; 2021 [cited year month day]. Available from: https://www.tctmd.com/slide/master-dapt-randomized-trial-abbreviated-antiplatelet-therapy-outcomes-high-bleeding-risk. 
  8. Escaned J, Cao D, Baber U, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J 2021;42:4624-34. https://doi.org/10.1093/eurheartj/ehab702
  9. Lee YJ, Suh Y, Kim JS, et al. Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk: the subanalysis from the TICO trial. Korean Circ J 2022;52:324-37. https://doi.org/10.4070/kcj.2021.0321
  10. Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020;323:2407-16. https://doi.org/10.1001/jama.2020.7580